Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
about
Risks associated with lentiviral vector exposures and prevention strategiesPre-exposure Prophylaxis for HIV Prevention: Why, What, Who and HowDrug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Pre-exposure prophylaxis for HIV prevention in women: current perspectivesHIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trialTenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now.PrEP implementation research in Africa: what is new?Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response.Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol.Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxisValues and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.Feasibility, Acceptability And Adherence With Short Term Hiv Pre-Exposure Prophylaxis In Female Sexual Partners Of Migrant Miners In Mozambique.A Review of HIV Pre-Exposure Prophylaxis: The Female PerspectiveClinical and public health implications of acute and early HIV detection and treatment: a scoping review.Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approachThe future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection."Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation.The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.HIV and Bone Complications: Understudied Populations and New Management Strategies.HIV preexposure prophylaxis for adolescents and young adults.Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.Willingness to use pre-exposure prophylaxis for HIV prevention among men who have sex with men in Malaysia: Findings from an online survey.The impact of HIV infection and socioeconomic factors on the incidence of gonorrhea: A county-level, US-wide analysis.Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis.Preexposure prophylaxis for men who have sex with men and transgender persons in early adopting countries: a narrative review.From intention to STI prevention: An online questionnaire on barriers and facilitators for discussing sexual risk behaviour among HIV nurses.Tackling HIV and AIDS: contributions by non-human primate models.Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelinesValidation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project.When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study.High Burden of HIV, Syphilis and HSV-2 and Factors Associated with HIV Infection Among Female Sex Workers in Tanzania: Implications for Early Treatment of HIV and Pre-exposure Prophylaxis (PrEP).Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.Predictors of HIV, HIV Risk Perception, and HIV Worry Among Adolescent Girls and Young Women in Lilongwe, Malawi.Potential Healthcare Insurance and Provider Barriers to Pre-Exposure Prophylaxis Utilization Among Young Men Who Have Sex with Men.Facilitators and Barriers to Pre-Exposure Prophylaxis Willingness Among Young Men Who Have Sex with Men Who Use Geosocial Networking Applications in California.HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography.PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists.
P2860
Q28065064-BEFBCF9F-6F7B-455C-B89E-39BBAE9AA747Q28080301-C2BC427E-BF9C-4488-98A1-CEE9FAF867DBQ30249113-7D276F28-6831-4BFC-A9D0-56F0E5E52E47Q33766562-6E316D75-8ADF-4F06-83D1-DE40E2E3A74AQ33848307-A1932EBA-F891-4511-A3E4-84E9EA479EABQ36146022-5E58CE7E-BF22-42EB-AC15-91A68815E4B0Q37352576-403B2349-C367-40D1-8024-92FF088D79C3Q37512411-70BFE220-FD73-4E09-9D76-EB4BC181384FQ37639989-9E397B3C-3B2C-4BEF-B026-D01B4C598BC6Q37661125-D5A33C88-19AB-4609-B25E-A3A243FC5850Q37736077-AF5FE438-C347-48AB-AFE2-BA47D205D191Q38641084-BD2F89CE-3BF2-4B4F-9BD6-D536A6EDF947Q38672579-B93D8EC5-7B18-4727-9B49-178AA3FAB048Q38686953-3D986420-3F44-413E-97E0-79CED1C03418Q38737364-6111B71B-5854-4B2F-80D1-78DDE99C592DQ38742497-6314706D-73F9-4FC0-A832-48567069973AQ38834636-9D3D329A-F8DC-41FA-94BE-D836D1050BDEQ38849706-E36C093C-9C61-4E75-AE0D-83C5D76E1E6AQ38978479-C3245F9D-1A31-4D63-A49D-03C41A1FB2E0Q39362420-F376B95A-270C-4365-A8FB-E5D569C428CFQ39488594-E8004821-7AB0-4B11-9E53-29D4DC05BF1EQ40048947-5063464E-7384-4399-877A-406B29CF5975Q40070635-D72401DB-E7D4-4F6A-8499-9CF19F48F353Q40072965-6B7522CE-34F1-477F-A0DA-D53847BD246CQ40073013-A9B341CD-3D95-4AD2-84C3-E60EE2EBBC42Q40153816-692739F9-E907-4794-80C3-8820C09787D1Q40191155-1D805DA6-856A-4462-AC4D-818A58D3579FQ40239354-22CB5951-84D3-407A-89B7-3FDFA1FB1F2BQ40281007-6DA6E175-7DDE-4E28-9407-E66C4D734717Q42334798-E70BC0F5-97BC-458E-94CA-08B8261911B2Q42364329-63977B39-3946-4A1E-81F8-D1AB66F3C1E4Q42376936-5FE2081E-FEF5-4CDE-BDC5-6946BFAC5351Q43923855-6B1557BB-6343-45AE-B32D-B43E5CB5FFFFQ46323872-FC7A65F6-1EDD-4851-B625-D9D2EEC5CE63Q46367980-F198FA51-967D-42D4-B507-0E1EDF48321BQ46440280-03B25871-10F0-4A62-A398-DE551480FC74Q46535667-5D9CDF26-026B-4B67-92F9-73539476CE78Q47098854-C860AF9C-B493-449F-9CF1-164C902DB7F2Q47107885-D2F66E8A-761C-48C5-B505-A1CE64F93283Q47140463-03AED116-D8D2-4A57-AEFB-3C9498077C48
P2860
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@ast
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@en
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@nl
type
label
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@ast
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@en
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@nl
prefLabel
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@ast
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@en
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@nl
P2093
P2860
P31
P50
P921
P1433
P1476
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
@en
P2093
Caitlin E Kennedy
Florence M Koechlin
Kevin R O'Reilly
Michelle Rodolph
Sarah L Dalglish
Virginia A Fonner
P2860
P304
P356
10.1097/QAD.0000000000001145
P407
P5008
P577
2016-05-05T00:00:00Z
2016-07-31T00:00:00Z